Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W5WZ
|
|||
Drug Name |
Tideglusib
|
|||
Synonyms |
NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Investigative | [2] | ||
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H14N2O2S
|
|||
Canonical SMILES |
C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43
|
|||
InChI |
1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
|
|||
InChIKey |
PMJIHLSCWIDGMD-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 865854-05-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:147398
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | COVID-19 papain-like proteinase (PL-PRO) | Target Info | Inhibitor | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | A Phase II Trial of Tideglusib in Alzheimer's Disease. J Alzheimers Dis. 2015;45(1):75-88. | |||
REF 2 | Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.